We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Australia Leads Effort To Improve Diagnosis of Genetic Disorders

By LabMedica International staff writers
Posted on 17 Nov 2008
Australian scientists are leading a global initiative to improve the diagnosis of genetic disorders and reduce errors in the reporting of genetic variations. More...


Over 60% of people worldwide will be affected by a genetic change at some point in their lives that can result in a range of diseases such as cystic fibrosis, epilepsy, and cancer.

The Human Genome Project completed in early 2000, succeeded mapping the human genome. However, of the 20,000 human genes mapped, only 3,000 have any information available on their variations.

The Australian-led global project, called the Human Variome Project, is being conducted by University of Melbourne (Australia) investigators and colleagues within the Florey Neuroscience Institutes (Melbourne, Australia), the department of medicine at the Royal Melbourne Hospital (Melbourne, Australia), and the Epilepsy Research Center (Melbourne, Australia), together with other scientists from around the globe.

The global initiative was published in the November 2006 issue of the journal Science. Prof. Richard Cotton, lead author of the study, convener of the Human Variome Project, and honorary researcher at the University of Melbourne said, "There is a staggering error rate of up to 40% [in] some reporting of genetic variations. This means clinicians and specialists cannot solely rely on the research literature to inform the life and death decisions of diagnosis and prognosis of genetic disorders.”

The Human Variome Project will produce standards for the storage, transmission, and use of genetic variation information, which for many will reduce the enormously time-consuming task of seeking data to assist in providing patients with information.

A range of pilot projects are being organized around the world that will examine how to systematically collect genetic, clinical, and biochemical information in either a country- specific or gene-specific manner. Countries already planning to participate in these projects include Australia, China, Japan, and Kuwait.

The project has the support of World Health Organization (WHO; Geneva, Switzerland), the United Nations Scientific and Cultural Organization (UNESCO), and the Organization for Economic Cooperation and Development (OECD) countries.

Related Links:
University of Melbourne
Florey Neuroscience Institutes
Department of Medicine at the Royal Melbourne Hospital
Epilepsy Research Center
World Health Organization
United Nations Scientific and Cultural Organization
Organization for Economic Cooperation and Development


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.